Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic? Podcast By cover art

Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic?

Could a twice yearly injectable pre-exposure prophylaxis drug help curb the 44-year old HIV epidemic?

Listen for free

View show details

About this listen

 The FDA approved lenacapavir, a twice-yearly injectable PrEP shown to be 99% effective in preventing HIV, though high cost may limit global access. A phase 3 trial found that adding pembrolizumab to standard care improved event-free survival in head and neck cancer, especially in patients with high PD-L1 expression. MASLD-related deaths in the U.S. have quadrupled since 2006, rising most sharply in older adults and rural areas, and are expected to continue increasing.
No reviews yet